A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Status:	Completed
Conditions:	Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	6/22/2018
Start Date:	December 2011
End Date:	January 2016

A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy

This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in
participants with locally advanced/inoperable or metastatic pancreatic cancer, and will
investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.

Inclusion:

- Unresectable or metastatic pancreas cancer; participants with previous radical surgery
for pancreas cancer are eligible after progression is documented

- Participants may have received previous adjuvant treatment with gemcitabine with or
without radiotherapy for pancreas cancer

- ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2

- Adequate organ function

- Have an estimated life expectancy of at least 12 weeks and in the judgment of the
investigator, will be able to complete at least 2 cycles of treatment

- Ability to perform the indicated functional performance measures at baseline

Exclusion:

- Prior systemic therapy for unresectable/metastatic pancreas cancer

- Any medical or psychiatric condition, orthopedic or neuromuscular conditions that
could limit participation or confound study results

- Currently taking medications that are considered both muscle building and performance
enhancing (for example, androgen therapies, or anabolic steroids)

We found this trial at

sites

Clinical Trial Facility in Calgary Alberta

Calgary, Alberta

from

Calgary,